Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881) [ID6496]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 9 April 2026Expected publication date: 28 April 2026